nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—ABCC5—Fluorouracil—head and neck cancer	0.567	0.675	CbGbCtD
Alprostadil—ABCC4—Fluorouracil—head and neck cancer	0.272	0.325	CbGbCtD
Alprostadil—Pain localised—Docetaxel—head and neck cancer	0.00781	0.0766	CcSEcCtD
Alprostadil—Fibrosis—Hydroxyurea—head and neck cancer	0.00607	0.0595	CcSEcCtD
Alprostadil—Fibrosis—Fluorouracil—head and neck cancer	0.00437	0.0428	CcSEcCtD
Alprostadil—Application site pain—Fluorouracil—head and neck cancer	0.00284	0.0278	CcSEcCtD
Alprostadil—Disseminated intravascular coagulation—Docetaxel—head and neck cancer	0.00252	0.0247	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—XRCC3—head and neck cancer	0.00244	0.0779	CbGpPWpGaD
Alprostadil—ABCC5—hair follicle—head and neck cancer	0.00234	0.0882	CbGeAlD
Alprostadil—Numbness—Vinblastine—head and neck cancer	0.00229	0.0225	CcSEcCtD
Alprostadil—Local reaction—Fluorouracil—head and neck cancer	0.00225	0.0221	CcSEcCtD
Alprostadil—Sensory loss—Vinblastine—head and neck cancer	0.00219	0.0215	CcSEcCtD
Alprostadil—PTGER2—trachea—head and neck cancer	0.00202	0.0761	CbGeAlD
Alprostadil—SLCO2A1—neck—head and neck cancer	0.00172	0.0647	CbGeAlD
Alprostadil—ABCC4—Fluoropyrimidine Activity—XRCC3—head and neck cancer	0.00169	0.054	CbGpPWpGaD
Alprostadil—ABCC5—Fluoropyrimidine Activity—DPYD—head and neck cancer	0.00162	0.0518	CbGpPWpGaD
Alprostadil—Numbness—Fluorouracil—head and neck cancer	0.00151	0.0148	CcSEcCtD
Alprostadil—Sensory loss—Fluorouracil—head and neck cancer	0.00144	0.0141	CcSEcCtD
Alprostadil—PTGIR—connective tissue—head and neck cancer	0.00141	0.0531	CbGeAlD
Alprostadil—SLCO2A1—parotid gland—head and neck cancer	0.0014	0.0527	CbGeAlD
Alprostadil—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.00137	0.0135	CcSEcCtD
Alprostadil—PTGER1—head—head and neck cancer	0.00134	0.0506	CbGeAlD
Alprostadil—SLCO2A1—saliva-secreting gland—head and neck cancer	0.00134	0.0505	CbGeAlD
Alprostadil—PTGIR—epithelium—head and neck cancer	0.00134	0.0504	CbGeAlD
Alprostadil—Redness—Docetaxel—head and neck cancer	0.00133	0.0131	CcSEcCtD
Alprostadil—Burning sensation—Docetaxel—head and neck cancer	0.0013	0.0127	CcSEcCtD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—head and neck cancer	0.0012	1	CrCbGaD
Alprostadil—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00118	0.0116	CcSEcCtD
Alprostadil—SLCO2A1—epithelium—head and neck cancer	0.00117	0.044	CbGeAlD
Alprostadil—ABCC5—Fluoropyrimidine Activity—SMUG1—head and neck cancer	0.00115	0.0368	CbGpPWpGaD
Alprostadil—ABCC4—Fluoropyrimidine Activity—DPYD—head and neck cancer	0.00112	0.0359	CbGpPWpGaD
Alprostadil—Sepsis—Fluorouracil—head and neck cancer	0.00108	0.0106	CcSEcCtD
Alprostadil—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00105	0.0103	CcSEcCtD
Alprostadil—Myocardial infarction—Vinblastine—head and neck cancer	0.00104	0.0102	CcSEcCtD
Alprostadil—SLCO2A1—trachea—head and neck cancer	0.00103	0.0389	CbGeAlD
Alprostadil—Swelling—Fluorouracil—head and neck cancer	0.00103	0.0101	CcSEcCtD
Alprostadil—PTGER2—lymph node—head and neck cancer	0.000992	0.0374	CbGeAlD
Alprostadil—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00099	0.00972	CcSEcCtD
Alprostadil—Haemoglobin—Vinblastine—head and neck cancer	0.00096	0.00941	CcSEcCtD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.000957	0.0305	CbGpPWpGaD
Alprostadil—Haemorrhage—Vinblastine—head and neck cancer	0.000955	0.00936	CcSEcCtD
Alprostadil—Hypoaesthesia—Vinblastine—head and neck cancer	0.00095	0.00932	CcSEcCtD
Alprostadil—Pharyngitis—Vinblastine—head and neck cancer	0.000948	0.00929	CcSEcCtD
Alprostadil—PTGIR—thyroid gland—head and neck cancer	0.000936	0.0352	CbGeAlD
Alprostadil—Lethargy—Fluorouracil—head and neck cancer	0.000924	0.00907	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TYMS—head and neck cancer	0.000924	0.0295	CbGpPWpGaD
Alprostadil—Injection site reaction—Docetaxel—head and neck cancer	0.000895	0.00878	CcSEcCtD
Alprostadil—Haemoglobin—Hydroxyurea—head and neck cancer	0.000875	0.00858	CcSEcCtD
Alprostadil—Influenza like illness—Docetaxel—head and neck cancer	0.000875	0.00858	CcSEcCtD
Alprostadil—Haemorrhage—Hydroxyurea—head and neck cancer	0.000871	0.00854	CcSEcCtD
Alprostadil—Cardiac arrest—Fluorouracil—head and neck cancer	0.000861	0.00845	CcSEcCtD
Alprostadil—PTGIR—head—head and neck cancer	0.00083	0.0313	CbGeAlD
Alprostadil—SLCO3A1—thyroid gland—head and neck cancer	0.000826	0.0311	CbGeAlD
Alprostadil—SLCO2A1—thyroid gland—head and neck cancer	0.000818	0.0308	CbGeAlD
Alprostadil—ABCC4—Fluoropyrimidine Activity—SMUG1—head and neck cancer	0.0008	0.0255	CbGpPWpGaD
Alprostadil—Sepsis—Docetaxel—head and neck cancer	0.000782	0.00767	CcSEcCtD
Alprostadil—Anaemia—Vinblastine—head and neck cancer	0.000768	0.00753	CcSEcCtD
Alprostadil—Erythema—Hydroxyurea—head and neck cancer	0.000758	0.00743	CcSEcCtD
Alprostadil—ABCC5—thyroid gland—head and neck cancer	0.000748	0.0282	CbGeAlD
Alprostadil—Swelling—Docetaxel—head and neck cancer	0.000741	0.00727	CcSEcCtD
Alprostadil—SLCO3A1—head—head and neck cancer	0.000733	0.0276	CbGeAlD
Alprostadil—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000728	0.00714	CcSEcCtD
Alprostadil—SLCO2A1—head—head and neck cancer	0.000726	0.0273	CbGeAlD
Alprostadil—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000721	0.00707	CcSEcCtD
Alprostadil—Convulsion—Vinblastine—head and neck cancer	0.00072	0.00706	CcSEcCtD
Alprostadil—Hypertension—Vinblastine—head and neck cancer	0.000718	0.00704	CcSEcCtD
Alprostadil—Anaemia—Hydroxyurea—head and neck cancer	0.000701	0.00687	CcSEcCtD
Alprostadil—Discomfort—Vinblastine—head and neck cancer	0.000699	0.00686	CcSEcCtD
Alprostadil—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000688	0.00675	CcSEcCtD
Alprostadil—Myocardial infarction—Fluorouracil—head and neck cancer	0.000684	0.00671	CcSEcCtD
Alprostadil—Urinary tract infection—Fluorouracil—head and neck cancer	0.000679	0.00666	CcSEcCtD
Alprostadil—Lethargy—Docetaxel—head and neck cancer	0.000667	0.00654	CcSEcCtD
Alprostadil—Thrombocytopenia—Vinblastine—head and neck cancer	0.000664	0.00651	CcSEcCtD
Alprostadil—Convulsion—Hydroxyurea—head and neck cancer	0.000657	0.00644	CcSEcCtD
Alprostadil—Sinusitis—Fluorouracil—head and neck cancer	0.000655	0.00642	CcSEcCtD
Alprostadil—Pain in extremity—Docetaxel—head and neck cancer	0.000654	0.00641	CcSEcCtD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.000646	0.0206	CbGpPWpGaD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—head and neck cancer	0.000646	0.0206	CbGpPWpGaD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TYMS—head and neck cancer	0.00064	0.0204	CbGpPWpGaD
Alprostadil—Discomfort—Hydroxyurea—head and neck cancer	0.000638	0.00625	CcSEcCtD
Alprostadil—PTGER1—G alpha (q) signalling events—KISS1—head and neck cancer	0.000631	0.0202	CbGpPWpGaD
Alprostadil—Haemoglobin—Fluorouracil—head and neck cancer	0.00063	0.00618	CcSEcCtD
Alprostadil—Rhinitis—Fluorouracil—head and neck cancer	0.000628	0.00616	CcSEcCtD
Alprostadil—Haemorrhage—Fluorouracil—head and neck cancer	0.000627	0.00615	CcSEcCtD
Alprostadil—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000624	0.00612	CcSEcCtD
Alprostadil—Pharyngitis—Fluorouracil—head and neck cancer	0.000622	0.0061	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.000619	0.0198	CbGpPWpGaD
Alprostadil—Oedema—Hydroxyurea—head and neck cancer	0.000619	0.00607	CcSEcCtD
Alprostadil—Infection—Hydroxyurea—head and neck cancer	0.000615	0.00603	CcSEcCtD
Alprostadil—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000606	0.00594	CcSEcCtD
Alprostadil—Skin disorder—Hydroxyurea—head and neck cancer	0.000601	0.00589	CcSEcCtD
Alprostadil—SLCO2B1—thyroid gland—head and neck cancer	0.000585	0.022	CbGeAlD
Alprostadil—PTGIR—lymph node—head and neck cancer	0.000581	0.0219	CbGeAlD
Alprostadil—Pain—Vinblastine—head and neck cancer	0.00058	0.00569	CcSEcCtD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.000565	0.018	CbGpPWpGaD
Alprostadil—Feeling abnormal—Vinblastine—head and neck cancer	0.000559	0.00548	CcSEcCtD
Alprostadil—Erythema—Fluorouracil—head and neck cancer	0.000546	0.00535	CcSEcCtD
Alprostadil—Dyspepsia—Hydroxyurea—head and neck cancer	0.000544	0.00534	CcSEcCtD
Alprostadil—Abdominal pain—Vinblastine—head and neck cancer	0.000536	0.00526	CcSEcCtD
Alprostadil—Pain—Hydroxyurea—head and neck cancer	0.000529	0.00519	CcSEcCtD
Alprostadil—PTGER1—G alpha (q) signalling events—GRP—head and neck cancer	0.00052	0.0166	CbGpPWpGaD
Alprostadil—SLCO2B1—head—head and neck cancer	0.000519	0.0196	CbGeAlD
Alprostadil—ABCC4—thyroid gland—head and neck cancer	0.000518	0.0195	CbGeAlD
Alprostadil—SLCO3A1—lymph node—head and neck cancer	0.000513	0.0193	CbGeAlD
Alprostadil—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00051	0.005	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00051	0.0163	CbGpPWpGaD
Alprostadil—SLCO2A1—lymph node—head and neck cancer	0.000508	0.0191	CbGeAlD
Alprostadil—Anaemia—Fluorouracil—head and neck cancer	0.000504	0.00495	CcSEcCtD
Alprostadil—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000497	0.00487	CcSEcCtD
Alprostadil—Renal failure—Docetaxel—head and neck cancer	0.000495	0.00486	CcSEcCtD
Alprostadil—Myocardial infarction—Docetaxel—head and neck cancer	0.000494	0.00484	CcSEcCtD
Alprostadil—Body temperature increased—Hydroxyurea—head and neck cancer	0.000489	0.0048	CcSEcCtD
Alprostadil—Asthenia—Vinblastine—head and neck cancer	0.000487	0.00477	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—TGFA—head and neck cancer	0.000478	0.0153	CbGpPWpGaD
Alprostadil—Convulsion—Fluorouracil—head and neck cancer	0.000473	0.00464	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—KISS1—head and neck cancer	0.000471	0.015	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.000465	0.0148	CbGpPWpGaD
Alprostadil—ABCC5—lymph node—head and neck cancer	0.000465	0.0175	CbGeAlD
Alprostadil—Diarrhoea—Vinblastine—head and neck cancer	0.000464	0.00455	CcSEcCtD
Alprostadil—ABCC4—head—head and neck cancer	0.00046	0.0173	CbGeAlD
Alprostadil—Discomfort—Fluorouracil—head and neck cancer	0.000459	0.0045	CcSEcCtD
Alprostadil—Haemoglobin—Docetaxel—head and neck cancer	0.000455	0.00446	CcSEcCtD
Alprostadil—Rhinitis—Docetaxel—head and neck cancer	0.000453	0.00445	CcSEcCtD
Alprostadil—Haemorrhage—Docetaxel—head and neck cancer	0.000452	0.00444	CcSEcCtD
Alprostadil—Hypoaesthesia—Docetaxel—head and neck cancer	0.00045	0.00441	CcSEcCtD
Alprostadil—Pharyngitis—Docetaxel—head and neck cancer	0.000449	0.0044	CcSEcCtD
Alprostadil—Dizziness—Vinblastine—head and neck cancer	0.000449	0.0044	CcSEcCtD
Alprostadil—Oedema—Fluorouracil—head and neck cancer	0.000445	0.00437	CcSEcCtD
Alprostadil—Asthenia—Hydroxyurea—head and neck cancer	0.000444	0.00435	CcSEcCtD
Alprostadil—Urethral disorder—Docetaxel—head and neck cancer	0.000443	0.00435	CcSEcCtD
Alprostadil—Infection—Fluorouracil—head and neck cancer	0.000442	0.00434	CcSEcCtD
Alprostadil—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000436	0.00428	CcSEcCtD
Alprostadil—Visual impairment—Docetaxel—head and neck cancer	0.000436	0.00428	CcSEcCtD
Alprostadil—Tachycardia—Fluorouracil—head and neck cancer	0.000435	0.00426	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000434	0.0139	CbGpPWpGaD
Alprostadil—Headache—Vinblastine—head and neck cancer	0.000425	0.00417	CcSEcCtD
Alprostadil—PTGIR—Endothelin Pathways—MAPK1—head and neck cancer	0.000424	0.0136	CbGpPWpGaD
Alprostadil—Diarrhoea—Hydroxyurea—head and neck cancer	0.000423	0.00415	CcSEcCtD
Alprostadil—Flushing—Docetaxel—head and neck cancer	0.00042	0.00412	CcSEcCtD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.000418	0.0133	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.000418	0.0133	CbGpPWpGaD
Alprostadil—Hypotension—Fluorouracil—head and neck cancer	0.000416	0.00408	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000411	0.0131	CbGpPWpGaD
Alprostadil—Dizziness—Hydroxyurea—head and neck cancer	0.000409	0.00401	CcSEcCtD
Alprostadil—Nausea—Vinblastine—head and neck cancer	0.000403	0.00395	CcSEcCtD
Alprostadil—Erythema—Docetaxel—head and neck cancer	0.000394	0.00386	CcSEcCtD
Alprostadil—Dyspepsia—Fluorouracil—head and neck cancer	0.000392	0.00384	CcSEcCtD
Alprostadil—Rash—Hydroxyurea—head and neck cancer	0.00039	0.00383	CcSEcCtD
Alprostadil—Dermatitis—Hydroxyurea—head and neck cancer	0.00039	0.00382	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—GRP—head and neck cancer	0.000388	0.0124	CbGpPWpGaD
Alprostadil—Headache—Hydroxyurea—head and neck cancer	0.000387	0.0038	CcSEcCtD
Alprostadil—Back pain—Docetaxel—head and neck cancer	0.000381	0.00374	CcSEcCtD
Alprostadil—Pain—Fluorouracil—head and neck cancer	0.000381	0.00373	CcSEcCtD
Alprostadil—Muscle spasms—Docetaxel—head and neck cancer	0.000379	0.00371	CcSEcCtD
Alprostadil—Nausea—Hydroxyurea—head and neck cancer	0.000367	0.0036	CcSEcCtD
Alprostadil—Feeling abnormal—Fluorouracil—head and neck cancer	0.000367	0.0036	CcSEcCtD
Alprostadil—Anaemia—Docetaxel—head and neck cancer	0.000364	0.00357	CcSEcCtD
Alprostadil—SLCO2B1—lymph node—head and neck cancer	0.000364	0.0137	CbGeAlD
Alprostadil—Syncope—Docetaxel—head and neck cancer	0.000353	0.00346	CcSEcCtD
Alprostadil—Body temperature increased—Fluorouracil—head and neck cancer	0.000352	0.00345	CcSEcCtD
Alprostadil—Loss of consciousness—Docetaxel—head and neck cancer	0.000346	0.00339	CcSEcCtD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.000344	0.011	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.000344	0.011	CbGpPWpGaD
Alprostadil—Cough—Docetaxel—head and neck cancer	0.000344	0.00337	CcSEcCtD
Alprostadil—Convulsion—Docetaxel—head and neck cancer	0.000341	0.00335	CcSEcCtD
Alprostadil—Hypertension—Docetaxel—head and neck cancer	0.00034	0.00333	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—TGFA—head and neck cancer	0.000332	0.0106	CbGpPWpGaD
Alprostadil—Dry mouth—Docetaxel—head and neck cancer	0.000328	0.00322	CcSEcCtD
Alprostadil—ABCC4—lymph node—head and neck cancer	0.000322	0.0121	CbGeAlD
Alprostadil—Oedema—Docetaxel—head and neck cancer	0.000321	0.00315	CcSEcCtD
Alprostadil—Infection—Docetaxel—head and neck cancer	0.000319	0.00313	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—KISS1—head and neck cancer	0.000318	0.0102	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—KISS1—head and neck cancer	0.000318	0.0102	CbGpPWpGaD
Alprostadil—Shock—Docetaxel—head and neck cancer	0.000316	0.0031	CcSEcCtD
Alprostadil—Pruritus—Fluorouracil—head and neck cancer	0.000315	0.00309	CcSEcCtD
Alprostadil—Thrombocytopenia—Docetaxel—head and neck cancer	0.000315	0.00309	CcSEcCtD
Alprostadil—Tachycardia—Docetaxel—head and neck cancer	0.000314	0.00308	CcSEcCtD
Alprostadil—Skin disorder—Docetaxel—head and neck cancer	0.000312	0.00306	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000306	0.00978	CbGpPWpGaD
Alprostadil—Diarrhoea—Fluorouracil—head and neck cancer	0.000305	0.00299	CcSEcCtD
Alprostadil—Hypotension—Docetaxel—head and neck cancer	0.0003	0.00295	CcSEcCtD
Alprostadil—Dizziness—Fluorouracil—head and neck cancer	0.000294	0.00289	CcSEcCtD
Alprostadil—Dyspepsia—Docetaxel—head and neck cancer	0.000283	0.00277	CcSEcCtD
Alprostadil—Rash—Fluorouracil—head and neck cancer	0.000281	0.00275	CcSEcCtD
Alprostadil—Dermatitis—Fluorouracil—head and neck cancer	0.00028	0.00275	CcSEcCtD
Alprostadil—Headache—Fluorouracil—head and neck cancer	0.000279	0.00274	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—EGFR—head and neck cancer	0.000278	0.00887	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—GSTM1—head and neck cancer	0.000278	0.00887	CbGpPWpGaD
Alprostadil—Pain—Docetaxel—head and neck cancer	0.000275	0.0027	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—KISS1—head and neck cancer	0.000266	0.0085	CbGpPWpGaD
Alprostadil—Feeling abnormal—Docetaxel—head and neck cancer	0.000265	0.0026	CcSEcCtD
Alprostadil—Nausea—Fluorouracil—head and neck cancer	0.000264	0.00259	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—GRP—head and neck cancer	0.000262	0.00837	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—GRP—head and neck cancer	0.000262	0.00837	CbGpPWpGaD
Alprostadil—Body temperature increased—Docetaxel—head and neck cancer	0.000254	0.00249	CcSEcCtD
Alprostadil—Abdominal pain—Docetaxel—head and neck cancer	0.000254	0.00249	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—KISS1—head and neck cancer	0.000242	0.00772	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000239	0.00761	CbGpPWpGaD
Alprostadil—Asthenia—Docetaxel—head and neck cancer	0.000231	0.00226	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000228	0.00728	CbGpPWpGaD
Alprostadil—Pruritus—Docetaxel—head and neck cancer	0.000227	0.00223	CcSEcCtD
Alprostadil—Diarrhoea—Docetaxel—head and neck cancer	0.00022	0.00216	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—GRP—head and neck cancer	0.000219	0.007	CbGpPWpGaD
Alprostadil—Dizziness—Docetaxel—head and neck cancer	0.000213	0.00208	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000212	0.00678	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—UROD—head and neck cancer	0.000203	0.00649	CbGpPWpGaD
Alprostadil—Rash—Docetaxel—head and neck cancer	0.000203	0.00199	CcSEcCtD
Alprostadil—Dermatitis—Docetaxel—head and neck cancer	0.000202	0.00199	CcSEcCtD
Alprostadil—Headache—Docetaxel—head and neck cancer	0.000201	0.00197	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—GRP—head and neck cancer	0.000199	0.00636	CbGpPWpGaD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—AKT1—head and neck cancer	0.000197	0.00629	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—GSTM1—head and neck cancer	0.000193	0.00615	CbGpPWpGaD
Alprostadil—Nausea—Docetaxel—head and neck cancer	0.000191	0.00187	CcSEcCtD
Alprostadil—PTGIR—GPCR downstream signaling—KISS1—head and neck cancer	0.00018	0.00574	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—KISS1—head and neck cancer	0.00018	0.00574	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KISS1—head and neck cancer	0.000163	0.00522	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KISS1—head and neck cancer	0.000163	0.00522	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000158	0.00504	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—GRP—head and neck cancer	0.000148	0.00473	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—GRP—head and neck cancer	0.000148	0.00473	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KISS1—head and neck cancer	0.000143	0.00456	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—VEGFA—head and neck cancer	0.000138	0.00442	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—GRP—head and neck cancer	0.000135	0.0043	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—GRP—head and neck cancer	0.000135	0.0043	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—head and neck cancer	0.000132	0.00421	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GRP—head and neck cancer	0.000118	0.00376	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STAT6—head and neck cancer	0.000114	0.00365	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—YAP1—head and neck cancer	0.000101	0.00323	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	9.96e-05	0.00318	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KISS1—head and neck cancer	9.65e-05	0.00308	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KISS1—head and neck cancer	9.65e-05	0.00308	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	9.48e-05	0.00303	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	9.48e-05	0.00302	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—PIK3CA—head and neck cancer	9.2e-05	0.00294	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NAT2—head and neck cancer	8.44e-05	0.00269	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	8.22e-05	0.00263	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GRP—head and neck cancer	7.95e-05	0.00254	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GRP—head and neck cancer	7.95e-05	0.00254	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STAT6—head and neck cancer	7.72e-05	0.00246	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STAT6—head and neck cancer	7.72e-05	0.00246	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	7.61e-05	0.00243	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—DPYD—head and neck cancer	7.4e-05	0.00236	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—IL2—head and neck cancer	7.22e-05	0.00231	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—YAP1—head and neck cancer	7.02e-05	0.00224	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—YAP1—head and neck cancer	6.83e-05	0.00218	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—YAP1—head and neck cancer	6.83e-05	0.00218	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IL2—head and neck cancer	6.25e-05	0.00199	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	6.14e-05	0.00196	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—IL2—head and neck cancer	5.84e-05	0.00187	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	5.81e-05	0.00185	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	5.53e-05	0.00176	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VEGFA—head and neck cancer	5.31e-05	0.00169	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL2—head and neck cancer	5.31e-05	0.00169	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—MAPK3—head and neck cancer	5.02e-05	0.0016	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	4.8e-05	0.00153	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—MAPK1—head and neck cancer	4.78e-05	0.00153	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOTCH1—head and neck cancer	4.56e-05	0.00145	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—MAPK3—head and neck cancer	4.27e-05	0.00136	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TYMS—head and neck cancer	4.22e-05	0.00135	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTM1—head and neck cancer	4.17e-05	0.00133	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CA—head and neck cancer	4.15e-05	0.00132	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—MAPK1—head and neck cancer	4.06e-05	0.0013	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—head and neck cancer	4.06e-05	0.0013	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—head and neck cancer	4.01e-05	0.00128	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GPX1—head and neck cancer	3.99e-05	0.00127	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP1A1—head and neck cancer	3.95e-05	0.00126	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—IL2—head and neck cancer	3.95e-05	0.00126	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—IL2—head and neck cancer	3.95e-05	0.00126	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	3.92e-05	0.00125	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CA—head and neck cancer	3.88e-05	0.00124	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—head and neck cancer	3.84e-05	0.00122	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOTCH1—head and neck cancer	3.78e-05	0.00121	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IL2—head and neck cancer	3.72e-05	0.00119	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL2—head and neck cancer	3.59e-05	0.00114	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL2—head and neck cancer	3.59e-05	0.00114	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CA—head and neck cancer	3.52e-05	0.00112	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—head and neck cancer	3.39e-05	0.00108	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—head and neck cancer	3.26e-05	0.00104	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—head and neck cancer	3.17e-05	0.00101	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—head and neck cancer	3.16e-05	0.00101	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL2—head and neck cancer	3.14e-05	0.001	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH1—head and neck cancer	3.08e-05	0.000982	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH1—head and neck cancer	3.08e-05	0.000982	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCND1—head and neck cancer	3.06e-05	0.000976	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MAPK3—head and neck cancer	2.99e-05	0.000956	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTEN—head and neck cancer	2.95e-05	0.000942	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MAPK3—head and neck cancer	2.88e-05	0.00092	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—MAPK3—head and neck cancer	2.88e-05	0.00092	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—head and neck cancer	2.88e-05	0.000919	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MAPK1—head and neck cancer	2.85e-05	0.000909	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—head and neck cancer	2.81e-05	0.000896	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MAPK1—head and neck cancer	2.74e-05	0.000876	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—MAPK1—head and neck cancer	2.74e-05	0.000876	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—head and neck cancer	2.74e-05	0.000875	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—head and neck cancer	2.74e-05	0.000875	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—head and neck cancer	2.66e-05	0.000851	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STAT3—head and neck cancer	2.64e-05	0.000842	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CA—head and neck cancer	2.62e-05	0.000837	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CA—head and neck cancer	2.62e-05	0.000837	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK3—head and neck cancer	2.52e-05	0.000805	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CA—head and neck cancer	2.47e-05	0.000789	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTEN—head and neck cancer	2.45e-05	0.000781	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK1—head and neck cancer	2.4e-05	0.000766	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—head and neck cancer	2.4e-05	0.000766	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—head and neck cancer	2.39e-05	0.000763	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CA—head and neck cancer	2.38e-05	0.00076	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CA—head and neck cancer	2.38e-05	0.00076	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—head and neck cancer	2.35e-05	0.00075	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—head and neck cancer	2.29e-05	0.00073	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—head and neck cancer	2.2e-05	0.000703	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—head and neck cancer	2.2e-05	0.000703	CbGpPWpGaD
Alprostadil—ABCC5—Disease—STAT3—head and neck cancer	2.19e-05	0.000699	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—head and neck cancer	2.14e-05	0.000683	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—head and neck cancer	2.14e-05	0.000683	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL2—head and neck cancer	2.12e-05	0.000676	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL2—head and neck cancer	2.12e-05	0.000676	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAPK3—head and neck cancer	2.09e-05	0.000667	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CA—head and neck cancer	2.08e-05	0.000664	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCND1—head and neck cancer	2.06e-05	0.000659	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCND1—head and neck cancer	2.06e-05	0.000659	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTEN—head and neck cancer	2.05e-05	0.000654	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—head and neck cancer	2.02e-05	0.000645	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—head and neck cancer	2.01e-05	0.000643	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTEN—head and neck cancer	1.99e-05	0.000636	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTEN—head and neck cancer	1.99e-05	0.000636	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAPK1—head and neck cancer	1.99e-05	0.000635	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—head and neck cancer	1.99e-05	0.000635	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—head and neck cancer	1.94e-05	0.000621	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—head and neck cancer	1.94e-05	0.000621	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—head and neck cancer	1.93e-05	0.000615	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—head and neck cancer	1.8e-05	0.000575	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—head and neck cancer	1.8e-05	0.000575	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STAT3—head and neck cancer	1.78e-05	0.000569	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STAT3—head and neck cancer	1.78e-05	0.000569	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CA—head and neck cancer	1.73e-05	0.000551	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK3—head and neck cancer	1.7e-05	0.000544	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK3—head and neck cancer	1.7e-05	0.000544	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—head and neck cancer	1.7e-05	0.000543	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK1—head and neck cancer	1.62e-05	0.000517	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK1—head and neck cancer	1.62e-05	0.000517	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—head and neck cancer	1.62e-05	0.000517	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—head and neck cancer	1.62e-05	0.000517	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—head and neck cancer	1.6e-05	0.00051	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CA—head and neck cancer	1.45e-05	0.000462	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—head and neck cancer	1.41e-05	0.00045	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CA—head and neck cancer	1.41e-05	0.000449	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CA—head and neck cancer	1.41e-05	0.000449	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—head and neck cancer	1.36e-05	0.000434	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—head and neck cancer	1.36e-05	0.000434	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—head and neck cancer	1.3e-05	0.000415	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—head and neck cancer	1.3e-05	0.000415	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—head and neck cancer	1.18e-05	0.000377	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—head and neck cancer	1.15e-05	0.000367	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—head and neck cancer	1.15e-05	0.000367	CbGpPWpGaD
